2018-06-25T13:09:56-05:00 2017-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650N BETHESDA MD 208142930 990 2017-01-01 133870223 INTERNATIONAL AIDS VACCINE INITIATIVE INC INTE 2128471111 125 BROAD STREET NO 9TH FL NEW YORK NY 10004 LOUIS D SCHWARTZ CFO 2128471111 2018-06-25 1 3019519090 2017 2022-09-23 18:48:47Z MARK FEINBERG 125 BROAD STREET NO 9TH FL NEW YORK NY 10004 80526964 0 X WWW.IAVI.ORG X 1996 DE GLOBAL NON-PROFIT INITIATIVE FOR HIV VACCINES AND OTHER BIOMEDICAL TOOLS TO PREVENT HIV INFECTION. 9 8 161 11 0 0 63919808 79435403 0 260438 986471 596174 116898 234949 65023177 80526964 17654908 17623273 0 0 25256275 27029476 0 0 1189062 31036756 40744716 73947939 85397465 -8924762 -4870501 89152233 81959513 42089479 38044228 47062754 43915285 X INTERNATIONAL AIDS VACCINE INITIATIVE (IAVI) IS A GLOBAL NON-PROFIT WHOSE MISSION IS TO ENSURE THE DEVELOPMENT OF HIV VACCINES AND OTHER BIOMEDICAL TOOLS TO PREVENT HIV INFECTION. 0 0 72689799 16462765 260438 RESEARCH AND DEVELOPMENT: WITH A FOCUSED RESEARCH AND DEVELOPMENT AGENDA, IAVI CATALYZES STAKEHOLDERS AROUND THE WORLD TO PROPEL THE SEARCH FOR AN HIV VACCINE. IAVI DESIGNS AND DEVELOPS VACCINE CANDIDATES AND CONDUCTS TRIALS AND RELATED EPIDEMIOLOGICAL RESEARCH IN PARTNERSHIP WITH MORE THAN 50 ACADEMIC, BIOTECHNOLOGY, PHARMACEUTICAL AND GOVERNMENTAL INSTITUTIONS. WITH PIONEERING RESEARCH, IAVI PRIORITIZES TWO SCIENTIFIC APPROACHES: ENGAGING THE IMMUNE SYSTEM TO BLOCK INFECTION, AND TRAINING IT TO RECOGNIZE AND DESTROY CELLS ALREADY INFECTED BY HIV. AS THE FIELD HAS EVOLVED, IAVI IS PREPARED TO CONTRIBUTE TO PREVENTION RESEARCH FOR OTHER INFECTIOUS DISEASES, AND TO INCORPORATE KNOWLEDGE FROM THAT WORK INTO ITS CORE SCIENTIFIC MISSION. HIV VACCINE CANDIDATES ARE PUT THROUGH A RIGOROUS PROCESS OF CLINICAL EVALUATION AMONG KEY POPULATIONS TO ESTABLISH THEIR SAFETY AND EFFICACY, AN EFFORT THAT ENABLES IAVI TO STRENGTHEN THE HEALTHCARE INFRASTRUCTURE AND SCIENTIFIC CAPACITY OF COUNTRIES WHERE OUR CLINICAL PARTNERS OPERATE. TO DATE, IAVI AND ITS PARTNERS HAVE DEVELOPED 32 HIV VACCINE AND PREVENTION CANDIDATES, ADVANCING 26 INTO EARLY-STAGE CLINICAL TRIALS INCLUDING THE FIRST HIV VACCINE TRIALS IN SUB-SAHARAN NATIONS THAT SHOULDER THE GREATEST HIV BURDEN. IAVI HAS CONDUCTED 30 EPIDEMIOLOGICAL STUDIES AND PROVIDED VOLUNTARY TESTING AND COUNSELING TO MORE THAN 680,000 INDIVIDUALS IN AFRICA. IAVI SUBSCRIBES TO THE HIGHEST SCIENTIFIC AND ETHICAL STANDARDS FOR CONDUCTING TRIALS, ONE THAT PROTECTS THE RIGHTS, WELL-BEING, AND DIGNITY OF TRIAL VOLUNTEERS. IAVI HAS ALSO LAUNCHED RESEARCH CONSORTIA TO BOOST THE NUMBER AND QUALITY OF NOVEL VACCINE CANDIDATES EVALUATED IN CLINICAL TRIALS AND TO ADDRESS MAJOR SCIENTIFIC PROBLEMS OF VACCINE DEVELOPMENT. A SIGNIFICANT PORTION OF THE VACCINE RESEARCH IAVI SUPPORTS IS CONDUCTED IN DEVELOPING COUNTRIES WHERE 95% OF ALL NEW HIV INFECTIONS OCCUR. 3490780 1160508 VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY: IAVI BELIEVES THAT SUPPORTIVE NATIONAL, REGIONAL, AND GLOBAL POLITICAL, ECONOMIC, AND SOCIETAL ENVIRONMENTS ARE CRITICAL TO THE FASTEST POSSIBLE DEVELOPMENT, APPROVAL, AND DISSEMINATION OF AN AIDS VACCINE. AS A MEMBER OF COALITIONS AND ON ITS OWN, IAVI CONVENES ADVOCATES, POLICYMAKERS, ACTIVISTS, AND REPRESENTATIVES OF THE COMMUNITIES HARDEST HIT BY HVI/AIDS TO RAISE AWARENESS AND STRENGTHEN ADVOCACY CAPACITY AROUND THE WORLD. 76180579 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 0 0 1 X 93 0 1 161 1 0 1 IN KE SF UK 0 0 0 0 0 0 0 0 X 9 8 0 0 1 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AL AR CA CT FL GA HI IL KS KY MD MA MI MN MS NH NJ NM NY NC OR PA RI SC TN UT VA WV WI X X PATRICK MOUTON 2128471137 125 BROAD STREET NO 9TH FL NEW YORK NY 10004 MARK FEINBERG PRESIDENT/CEO 35.00 X X 545949 0 34287 ERIC PAUL GOOSBY BOARD CHAIR 2.00 X X 0 0 0 ANNE M VANLENT BOARD VICE CHAIR & TREASURER 2.00 X X 0 0 0 ROBERT GOLDBERG BOARD MEMBER 1.00 X 0 0 0 ADEL AF MAHOUD BOARD MEMBER 1.00 X 0 0 0 FRANCINE NTOUMI BOARD MEMBER 1.00 X 0 0 0 MARIJKE WIJNROKS BOARD MEMBER 1.00 X 0 0 0 MONCEF SLAOUI BOARD MEMBER 1.00 X 0 0 0 PURNIMA MANE BOARD MEMBER 1.00 X 0 0 0 LABEEB ABBOUD SECRETARY, SR VP, GENERAL COUNSEL 35.00 X 365455 0 55357 LOUIS SCHWARTZ CHIEF FINANCIAL OFFICER 35.00 X 308531 0 55357 ANTHONY MUSYOKA HUMAN RESOURCES, ASST. SECRETARY 35.00 X 296021 0 55357 THOMAS HASSELL V.P. VACCINE DEVELOPMENT R&D 35.00 X 345576 0 55357 CHRISTOPHER PARKS EXECUTIVE DIR., VIRAL VACCINES 35.00 X 331786 0 52106 FRAN PRIDDY EXECUTIVE DIR., CHIEF MEDICAL OFF. 35.00 X 297292 0 29700 ANTU DEY SNR. DIR., HIV ENVELOPE IMMUN. DEV'L 35.00 X 288448 0 55398 MARGARET T KEANE V.P. GLOBAL ALL. & PRODUCT OPT. 35.00 X 259501 0 33413 3038559 0 426332 80 0 1 0 EMMES CORPORATION 401 N WASHINGTON STREET ROCKVILLE MD 20850 CLINICAL RESEARCH STUDIES 711810 AUSTRALIAN BIOLOGICS PTY LTD PO BOX 587 CRAIGIEBURN VICTORIA AS 3064 REGULATORY CONSULTANT 436211 VEDDER PRICE PC 8677 SOLUTION CENTER CHICAGO IL 606778006 LEGAL SERVICES 384947 ROUTES 2 RESULTS 5 PARK CT PYRFORD RD WEST BYFLEET SURREY UK KT1 46SD VIDEO ETHNOGRAPHY 193860 CCARL SARL RUE DES PAQUIS 16 1201 GENEVA SZ PROGRAM CONSULTING 137173 7 35479315 43956088 46950 79435403 CONTRACT SERVICE FEES 900099 260438 260438 260438 596174 596174 MISCELLANEOUS 900099 234949 234949 234949 80526964 260438 0 831123 3254066 3254066 14369207 14369207 1716314 249501 1397184 69629 20146708 16132821 3590299 423588 1520843 1226088 261299 33456 2311942 1806476 451976 53490 1333669 1007675 295882 30112 484730 375104 109626 123505 123505 228250 228250 34815 34815 632843 193482 354056 85305 646109 375710 263206 7193 685465 547029 78793 59643 3005219 2484474 430239 90506 2249717 1994373 202201 53143 489801 463989 23566 2246 1597387 1549899 40322 7166 298662 210389 84629 3644 RESEARCH&CLINICAL SVCS. 25025814 24856964 168850 LAB SUPPLIES/EQUIPMENT 4334870 4334370 500 EQUIPMENT MAINT. 617989 544435 71599 1955 SUBSCRIPTIONS & PUBS. 125051 108870 2546 13635 164489 95657 43231 25601 85397465 76180579 8027824 1189062 54335419 49308658 19740832 18982348 147338 90200 181545 180912 45884349 38273460 9076757 7610889 5451968 5601994 218374 184512 89152233 81959513 5320961 5633347 5113044 2210932 27923349 26672679 382494 269825 3349631 3257445 42089479 38044228 X 32402563 29886074 14660191 14029211 47062754 43915285 89152233 81959513 X -4870501 -92599 1815631 X 0 1 X 1 1 1 X 63996178 50593210 71447864 63919808 79435403 329392463 63996178 50593210 71447864 63919808 79435403 329392463 103929286 225463177 1225832 775037 694495 538881 596174 3830419 1030216 587195 505075 116898 234948 2474332 335697214 1302550 0.67160 0.76470 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2013 AMOUNT: $ 209,558. 2014 AMOUNT: $ 70,410. 2015 AMOUNT: $ 146,897. 2016 AMOUNT: $ 54,683. 2017 AMOUNT: $ 100,289. COLLABORATIVE AGREEMENT - 2013 AMOUNT: $ 250,000. 2014 AMOUNT: $ 250,000. WRITE OFF DEFERRED RENT - 2013 AMOUNT: $ 135,063. INNOVATION FUND RETURNED - 2013 AMOUNT: $ 353,000. LOAN FORGIVENESS - 2013 AMOUNT: $ 82,595. 2014 AMOUNT: $ 77,932. 2015 AMOUNT: $ 74,118. 2016 AMOUNT: $ 62,215. 2017 AMOUNT: $ 67,456. WRITE OFF PROVISION FOR RISK - 2014 AMOUNT: $ 188,853. 2015 AMOUNT: $ 284,060. VAT REFUND - 2017 AMOUNT: $ 67,203. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 228250 228250 85169215 85397465 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 150000 205000 227000 228250 810250 250000 250000 250000 250000 1000000 1500000 19883650 12704361 7179289 26000699 25569099 431600 7610889 DEFERRED RENT PAYABLE 2726730 DEFERRED COMPENSATION PAYABLE 530715 3257445 X 79727081 -92599 73501 -19098 79746179 34815 745970 780785 80526964 85512004 1309862 1309862 84202142 34815 1160508 1195323 85397465 PART X, LINE 2: FOR THE YEAR ENDED DECEMBER 31, 2017, MANAGEMENT OF IAVI HAS DOCUMENTED ITS CONSIDERATION OF FASB ASC 740-10, INCOME TAXES, THAT PROVIDES GUIDANCE FOR REPORTING UNCERTAINTY IN INCOME TAXES AND HAS DETERMINED THAT NO MATERIAL UNCERTAIN TAX POSITIONS QUALIFY FOR EITHER RECOGNITION OR DISCLOSURE IN THE CONSOLIDATED FINANCIAL STATEMENTS. PART XI, LINE 2D - OTHER ADJUSTMENTS: REVENUE OF STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE 73,501. INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. PART XI, LINE 4B - OTHER ADJUSTMENTS: INTER-COMPANY REVENUE, ELIMINATED IN CONSOLIDATED AUDIT 745,970. REPORT BUT INCLUDED IN IAVI, INC. FORM 990. PART XII, LINE 2D - OTHER ADJUSTMENTS: EXPENSES OF STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE 1,201,753. INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. EXPENSES OF IAVI INDIA, INCLUDED IN CONSOLIDATED AUDIT 108,109. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. PART XII, LINE 4B - OTHER ADJUSTMENTS: INTER-COMPANY EXPENSES, ELIMINATED IN CONSOLIDATED AUDIT 1,160,508. REPORT BUT INCLUDED IN IAVI, INC. FORM 990. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 5298921 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 502119 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 8568167 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 424353 EUROPE (INCLUDING ICELAND & GREENLAND) 1 5 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 1335849 NORTH AMERICA 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 639710 SUB-SAHARAN AFRICA 2 21 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 3327257 SOUTH ASIA 1 15 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 1102760 4 41 0 0 4 41 21199136 0 21199136 EUROPE (INCLUDING ICELAND & GREENLAND) VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY 1160508 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH&DEVELOPMENT 2149064 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 1641294 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 1385936 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 1385443 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 1345917 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 877924 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH&DEVELOPMENT 644386 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 582692 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 497177 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 471537 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH&DEVELOPMENT 435045 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH&DEVELOPMENT 304987 WIRE TRANSFER SOUTH ASIA RESEARCH&DEVELOPMENT 296305 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 283996 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH&DEVELOPMENT 180667 WIRE TRANSFER SOUTH ASIA RESEARCH&DEVELOPMENT 152500 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH&DEVELOPMENT 146693 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 96251 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH&DEVELOPMENT 93236 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH&DEVELOPMENT 78432 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH&DEVELOPMENT 55353 WIRE TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH&DEVELOPMENT 50551 WIRE TRANSFER SOUTH ASIA RESEARCH&DEVELOPMENT 30000 WIRE TRANSFER SOUTH ASIA RESEARCH&DEVELOPMENT 23314 WIRE TRANSFER 21 4 1 0 0 0 0 0 PART I, LINE 2: THE ORGANIZATION HAS A COMPLIANCE UNIT THAT MONITORS THE ADHERENCE OF SUB-GRANTEES TO THE CONTRACT AND DONOR TERMS WHICH INCLUDES REVIEW OF 2 CFR 200. ROUTINE COMPLIANCE AND SUBSTANTIVE AUDITS ARE PERFORMED BY A COMPLIANCE OFFICER LOCATED IN EAST AFRICA. ROUTINE INTERNAL CONTROL QUESTIONNAIRES, AND IN-DEPTH REVIEW OF QUARTERLY REPORTS OF SUB-GRANTEES TAKES PLACE ON A REGULAR BASIS. 1 THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD LA JOLLA CA 92037 330435954 501(C)(3) 1300534 RESEARCH & DEVELOPMENT EMORY UNIVERSITY 1599 CLIFTON ROAD ATLANTA GA 30332 580566256 501(C)(3) 850092 RESEARCH & DEVELOPMENT SEATTLE BIOMEDICAL RESEARCH INSTITUTE 307 WETLAKE AVENUE N STE 500 SEATTLE WA 981095240 910961784 501(C)(3) 306770 RESEARCH & DEVELOPMENT UNIVERSITY OF CALIFORNIA SAN FRANCISCO 3333 CALIFORNIA STREET SUITE 315 SAN FRANCISCO CA 94158 943067788 501(C)(3) 263736 RESEARCH & DEVELOPMENT NORTHWESTERN UNIVERSITY 750 N LAKE SHORE DRIVE 7TH FLOOR CHICAGO IL 60611 362167817 501(C)(3) 237806 RESEARCH & DEVELOPMENT UNVIERSITY OF ALABAMA AT BIRMINGHAM 701 20TH STREET S-AB 921 BIRMINGHAM AL 35294 636005396 501(C)(3) 182631 RESEARCH & DEVELOPMENT NATIONAL INSTITUTE OF ALLERGY-INFECTIOUS DISEASES 6610 ROCKLEDGE DRIVE RM 2800 BETHESDA CA 208926606 530196960 GOVERNMENT 100000 RESEARCH & DEVELOPMENT SAINT LOUIS UNIVERSITY 3700 WEST PINE MALL FUSZ HALL 357 SAINT LOUIS MO 63108 430654872 501(C)(3) 11149 RESEARCH & DEVELOPMENT 8 0 PART I, LINE 2: THE ORGANIZATION HAS A COMPLIANCE UNIT THAT MONITORS THE ADHERENCE OF SUB-GRANTEES TO THE CONTRACT AND DONOR TERMS WHICH INCLUDES REVIEW OF 2 CFR 200. REVIEW OF 2 CFR 200 AUDITS AND IN-DEPTH REVIEW OF QUARTERLY REPORTS OF SUB-GRANTEES TAKES PLACE ON A REGULAR BASIS. X X X X X 0 0 0 0 0 0 0 1 0 MARK FEINBERG PRESIDENT/CEO 482419 0 61333 0 2197 0 29700 0 4587 0 580236 0 0 0 LABEEB ABBOUD SECRETARY, SR VP, GENERAL COUNSEL 313888 0 31791 0 19776 0 29700 0 25657 0 420812 0 0 0 LOUIS SCHWARTZ CHIEF FINANCIAL OFFICER 278418 0 28256 0 1857 0 29700 0 25657 0 363888 0 0 0 ANTHONY MUSYOKA HUMAN RESOURCES, ASST. SECRETARY 268010 0 26739 0 1272 0 29700 0 25657 0 351378 0 0 0 THOMAS HASSELL V.P. VACCINE DEVELOPMENT R&D 313808 0 29578 0 2190 0 29700 0 25657 0 400933 0 0 0 CHRISTOPHER PARKS EXECUTIVE DIR., VIRAL VACCINES 275052 0 54958 0 1776 0 29700 0 22406 0 383892 0 0 0 FRAN PRIDDY EXECUTIVE DIR., CHIEF MEDICAL OFF. 272220 0 23800 0 1272 0 29700 0 0 0 326992 0 0 0 ANTU DEY SNR. DIR., HIV ENVELOPE IMMUN. DEV'L 241112 0 46154 0 1182 0 27145 0 28253 0 343846 0 0 0 MARGARET T KEANE V.P. GLOBAL ALL. & PRODUCT OPT. 257245 0 0 0 2256 0 19300 0 14113 0 292914 0 0 0 PART I, LINE 7 BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II). NOODLE FOX MEDIA THE OWNER OF THE ENTITY IS A FAMILY MEMBER (SPOUSE) OF AN OFFICER OF IAVI. 73930 IAVI HAS A CONSULTING AGREEMENT WITH NOODLE FOX MEDIA, TO PROVIDE MANAGING EDITOR SERVICES FOR IAVI REPORT. THE CONSULTANT WAS SELECTED ON A SOLE SOURCE BASIS, DUE TO UNIQUE SKILL AND EXPERIENCE. THE CONSULTANT HAD PREVIOUSLY SERVED AT IAVI AS MANAGING EDITOR FOR IAVI REPORT, AND BROUGHT RELEVANT SUBSTANTIVE KNOWLEDGE, SCIENTIFIC CONTACTS, AND EXPERTISE IN SCIENCE WRITING, EDITING AND MANAGING THE PUBLICATION PROCESS. THE AGREEMENT WAS ESTABLISHED ON AN ARMS-LENGTH BASIS BY THE ORGANIZATION. 0 X SOFTWARE 1 46950 FMV 0 0 0 PART I, COLUMN (B): THIS COLUMN INCLUDES THE NUMBER OF CONTRIBUTIONS RECEIVED. FORM 990, PART VI, SECTION A, LINE 4 IAVI AMENDED ITS BYLAWS IN MARCH 2017 TO REFLECT AMENDMENTS TO THE NEW YORK NON-PROFIT REVITALIZATION ACT OF 2013. THE FOLLOWING SUBSTANTIVE CHANGES WERE MADE: - ALLOWED A BROADER CATEGORY OF DIRECTORS TO QUALIFY AS INDEPENDENT BY NARROWING THE TYPES OF PAYMENTS THAT WILL DISQUALIFY A DIRECTOR FROM BEING CONSIDERED INDEPENDENT; - CLARIFIED THAT THE INDEPENDENCE DISQUALIFICATIONS APPLY TO "KEY PERSONS" WHO ARE INDIVIDUALS WITH SPECIFIED POWER OR INFLUENCE OVER THE CORPORATION, REGARDLESS OF WHETHER THEY ARE DIRECTORS, OFFICERS, EMPLOYEES OR NON-EMPLOYEES; AND - PROVIDED THAT COMMITTEES OF THE BOARD CONSIST OF AT LEAST 3 MEMBERS. FORM 990, PART VI, SECTION B, LINE 11B THE AUDIT AND FINANCE COMMITTEE REVIEWED AND APPROVED THE FORM 990 IN DETAIL WITH THE CONTROLLER AND CFO. IT WAS THEN SENT TO THE FULL BOARD BEFORE IT WAS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C IAVI HAS A CONFLICT OF INTEREST POLICY WHICH APPLIES TO ALL DIRECTORS, OFFICERS, KEY PERSONS, EMPLOYEES, CONSULTANTS AND ADVISORY COMMITTEE MEMBERS. THE POLICY REQUIRES THAT ALL DIRECTORS, OFFICERS, KEY PERSONS, EMPLOYEES AND ADVISORY COMMITTEE MEMBERS FILE AN ANNUAL DISCLOSURE FORM, INDICATING WHETHER THERE ARE ANY POSSIBLE OR ACTUAL CONFLICTS AS DEFINED UNDER THE POLICY. IN ADDITION, ALL ARE REQUIRED TO DISCLOSE ANY POSSIBLE OR ACTUAL CONFLICTS ON AN ONGOING BASIS. ANNUAL DISCLOSURE FORMS, AS WELL OTHER CONFLICT OF INTEREST DISCLOSURES THAT ARISE DURING THE YEAR, ARE FILED WITH AND REVIEWED BY THE GENERAL COUNSEL'S OFFICE. IN ADDITION, THE AUDIT & FINANCE COMMITTEE REVIEWS CONFLICT OF INTEREST DISCLOSURES THAT INVOLVE A DIRECTOR, OFFICER, OR KEY PERSON. IN EACH CASE, THE REVIEW ENSURES THAT ANY CONFLICT OF INTEREST OR POSSIBLE CONFLICT OF INTEREST IS PROPERLY ADDRESSED, MITIGATED, AND/OR MANAGED. CONFLICT OF INTEREST DISCLOSURES ARE SUMMARIZED AND PROVIDED TO THE CHAIR OF THE AUDIT & FINANCE COMMITTEE FOR REVIEW BY THE AUDIT & FINANCE COMMITTEE. IF ANY CONFLICT OF INTEREST OR POSSIBLE CONFLICT OF INTEREST DISCLOSURE INVOLVES THE CHAIR OF THE AUDIT & FINANCE COMMITTEE, THE COMMITTEE MEETS WITHOUT THE CHAIR. FORM 990, PART VI, SECTION B, LINE 15 ONCE EVERY TWO YEARS, THE COMPENSATION COMMITTEE OF THE BOARD, COMMISSIONS A COMPENSATION SURVEY OF THE CEO'S COMPENSATION PACKAGE. THE SURVEY COMPARES COMPENSATION PACKAGES OF CEOS OF ORGANIZATIONS THAT ARE COMPARABLE TO IAVI. THE COMMITTEE REVIEWS THE RESULTS OF THE SURVEY AND RECOMMENDATIONS MADE, DISCUSSES THIS WITH THE BOARD BEFORE PROVIDING SPECIFIC GUIDANCE AND APPROVAL TO IAVI'S MANAGEMENT. THE COMPENSATION COMMITTEE DETERMINES THE APPROPRIATE PACKAGE FOR THE CEO AND THE BOARD CHAIR SHARES THIS INFORMATION WITH HUMAN RESOURCES FOR IMPLEMENTATION. IAVI ENGAGES AN EXTERNAL SPECIALIZED FIRM WITH EXPERTISE TO CONDUCT THE SURVEY AND PROVIDE RECOMMENDATION TO THE COMPENSATION COMMITTEE. THE DELIBERATIONS OF THE COMPENSATION COMMITTEE OF THE BOARD ARE DOCUMENTED IN THE COMPENSATION COMMITTEE MINUTES FOR EACH MEETING OF THE MEMBERS. ALSO THE SAME IS CAPTURED IN THE BOARD MINUTES AS REPORTED OUT BY THE COMPENSATION COMMITTEE CHAIR FOR BOARD DISCUSSIONS AND APPROVAL. THE LAST COMPENSATION REVIEW TOOK PLACE IN DECEMBER 2017. IN CONJUNCTION WITH THE CEO'S COMPENSATION REVIEW, THE COMPENSATION COMMITTEE OF THE BOARD ALSO COMMISSIONS AN EXTERNAL COMPARATIVE COMPENSATION SURVEY OF ORGANIZATIONS SIMILAR TO IAVI, IN WHICH THE PACKAGES OF ALL OTHER OFFICERS AND KEY EMPLOYEES ARE BENCHMARKED AGAINST THE LABOR MARKET TO DETERMINE APPROPRIATENESS OF PAY. THE COMMITTEE REVIEWS THE RESULTS AND RECOMMENDATIONS FROM THIS SURVEY AND PROVIDES MANAGEMENT WITH SPECIFIC GUIDANCE IN ADDRESSING ANY DISPARITIES. USING BENCHMARK JOB CLASSIFICATIONS, ONCE EVERY 2 YEARS IAVI COMMISSIONS A COMPENSATION SURVEY, ACROSS ALL ITS OFFICES TO DETERMINE THE COMPETITIVENESS OF ITS COMPENSATION PROGRAMS AND TO ENABLE THE ORGANIZATION TO CONTINUE TO ATTRACT AND RETAIN THE RIGHT TALENT IN THESE VARIOUS MARKETS. IN MOST CASES THE LOCAL LABOR MARKET IS CONSIDERED AND FOR CERTAIN POSITIONS, REGIONAL MARKETS MUST BE TARGETED. THE RESULTS OF EACH SURVEY ARE REVIEWED WITH THE COMPENSATION COMMITTEE OF THE BOARD, WHICH GIVES MANAGEMENT OVERALL GUIDANCE ON COMPENSATION DIRECTION. BASED ON RECOMMENDATIONS AND GUIDANCE OF THE COMPENSATION COMMITTEE, THE EXECUTIVE OFFICE AND HUMAN RESOURCES COMMUNICATE CHANGES TO ANY AFFECTED EMPLOYEES. ANY COMPENSATION CHANGES ARE DETERMINED BASED ON EXTERNAL COMPETIVENESS RELATIVE INTERNAL VALUE, INDIVIDUAL PERFORMANCE, TEAM DYNAMIC, AND IAVI'S ABILITY TO PAY. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE ON ITS WEBSITE. FORM 990, PART XI, LINE 9: FOREIGN EXCHANGE GAIN 1,815,631. IAVI LAB LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 262031769 LAB RESEARCH DE 0 6524890 IAVI INC STICHTING IAVI VAN DIEMENSTRAAT 48 1013 NH AMSTERDAM NL RESEARCH SUPPORT NL N/A N/A IAVI INC 1 IAVI INDIA 4 FACTORY ROAD GROUND FLOOR ANSARI NAGAR WEST NEW DELHI-110029 IN RESEARCH SUPPORT IN N/A N/A IAVI INC 1 IAVI HOLDING LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 262032322 HOLDING COMPANY DE IAVI INC C 1.00000 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 STICHTING IAVI B 1160508 ACTUAL